1 of 1
Story summary
- A nationwide Class II recall is issued for Viatris' Xanax XR lot #8177156 after U.S. Food and Drug Administration (FDA) identified dissolution standards failure.
- The affected 3 mg extended-release tablets are in 60-tablet bottles, expiring February 28, 2027.
- Viatris initiated the recall after not meeting quality control specifications and concerns about dosage delivery.
- No adverse reactions have been reported, and the FDA has not disclosed the number of affected bottles.
